These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21781158)

  • 1. Decision-making under conditions of uncertainty-what can we learn from palivizumab?
    Burls A; Sandercock J
    Acta Paediatr; 2011 Oct; 100(10):1302-5. PubMed ID: 21781158
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-life wheezing and respiratory syncytial virus prevention.
    Lemanske RF
    N Engl J Med; 2013 May; 368(19):1839-41. PubMed ID: 23656652
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.
    Groothuis JR
    Pediatr Infect Dis J; 2001 Jun; 20(6):628-30. PubMed ID: 11419509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are we too passive in our attempts to prevent respiratory syncytial virus infection in Northern Canada?
    Moraes T
    Can Respir J; 2014; 21(3):163-4. PubMed ID: 24914608
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants.
    Young J
    Respir Med; 2002 Apr; 96 Suppl B():S31-5. PubMed ID: 11996402
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic results of palivizumab prophylaxis using vial sharing on immunisation days.
    Ovalı F; Gürsoy T; Erçin S; Yavuzcan Öztürk D; Karatepe HÖ; Karatekin G
    J Paediatr Child Health; 2013 Feb; 49(2):159. PubMed ID: 23418714
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on palivizumab (Synagis).
    Moler FW; Brown RW; Faix RG; Gilsdorf JR
    Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention of respiratory syncytial virus bronchiolitis].
    Marchac V
    Arch Pediatr; 2006 Dec; 13 Suppl 5():S12-7. PubMed ID: 17550819
    [No Abstract]   [Full Text] [Related]  

  • 14. Palivizumab: a debate about funding.
    Fitzgerald DA; Isaacs D; Tobin B
    J Paediatr Child Health; 2012 May; 48(5):373-7. PubMed ID: 22296413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
    Bollani L; Baraldi E; Chirico G; Dotta A; Lanari M; Del Vecchio A; Manzoni P; Boldrini A; Paolillo P; Di Fabio S; Orfeo L; Stronati M; Romagnoli C;
    Ital J Pediatr; 2015 Dec; 41():97. PubMed ID: 26670908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
    Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
    N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
    Domachowske J; Madhi SA; Simões EAF; Atanasova V; Cabañas F; Furuno K; Garcia-Garcia ML; Grantina I; Nguyen KA; Brooks D; Chang Y; Leach A; Takas T; Yuan Y; Griffin MP; Mankad VS; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):892-894. PubMed ID: 35235733
    [No Abstract]   [Full Text] [Related]  

  • 20. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.